Crizotinib Receives Breakthrough Therapy Designation for ROS1-Positive NSCLC

Get Permission

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to crizotinib (Xalkori) for the potential treatment of patients with ROS1-positive non–small cell lung cancer (NSCLC). Crizotinib currently is FDA-approved for the treatment of patients with metastatic NSCLC whose tumors are anaplastic lymphoma kinase (ALK)-positive.

The Breakthrough Therapy designation was based on data from an expansion cohort of a global phase I study that evaluated crizotinib in 50 patients with ROS1-positive advanced NSCLC. These data, published last year in The New England Journal of Medicine,1 demonstrated that crizotinib exhibited marked antitumor activity in patients with ROS1-positive advanced NSCLC. ■


1. Shaw AT, Ou S-HI, Bang Y-J, et al: Crizotinib in ROS1-rearranged non-small cell lung cancer. N Engl J Med 371:1963-1971, 2015.





By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.